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Summary
Background: Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis.
Aims: To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus.
Methods: PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016 . Comparative trials of second or third trimester tenofovir administration vs. controls for patients with chronic hepatitis B infection and non-comparative case series assessing mother to child transmission rates and evaluating maternal and foetal safety outcomes were included.
Results: Ten studies (one randomised controlled trial, four non-randomised controlled trials and five case series) that enrolled 733 women were included. The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77% (odds ratio=0.23, 95% confidence intervals=0.10-0.52, P=.0004) without heterogeneity (I 2 =0%). In the case series analysis (134 pregnancies), only two cases (1.5%) of mother to child transmission with extremely high maternal viral load and non-compliance to treatment were identified. Maternal and foetal safety parameters including congenital malformation and foetal death were re-assuring.
Conclusions: For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine.
Tenofovir is safe and tolerable for both the mother and foetus.
| INTRODUCTION

Chronic hepatitis B virus (HBV) infection is a global public health
issue affecting approximately 240 million people, and more than 600 000 people die annually because of HBV complications, according to World Health Organization (WHO) estimates. 1 In highly endemic areas, especially the Asia Pacific region, mother to child transmission (MTCT) accounts for the majority of infections. [2] [3] [4] If untreated, the likelihood of chronicity depends on what age a person acquired the infection (80%-90% of infants vs. <5% of adults). 5, 6 The recent universal newborn vaccination program using a combination of active and passive immunoprophylaxis led to a significant *These authors contributed equally to this work. As part of AP&T's peer-review process, a technical check of this meta-analysis was performed by Dr Y Yuan. The Handling Editor for this article was Professor Geoffrey Dusheiko, and it was accepted for publication after full peer-review.
reduction in the MTCT rate, from 90% to 10%. [7] [8] [9] In spite of this combination strategy, infants born to mothers with high maternal viral DNA levels (more than 10 6 copies/mL) with positive maternal hepatitis B envelope antigen (HBeAg) showed 10%-30% immunoprophylaxis failure compared to less than 3% in those with a low maternal viral load (less than 10 6 copies/mL). [10] [11] [12] [13] [14] [15] [16] Therefore, the idea has emerged from antepartum anti-viral therapy for pregnant women with high maternal HBV DNA levels to help achieve global eradication of chronic HBV infection.
Among the oral anti-HBV agents approved by the United States
Food and Drug Administration (FDA), lamivudine (GlaxoSmithKline, Middlesex, United Kingdom), telbivudine (Norvatis, Basel, Switzerland), and tenofovir (Gilead Sciences, Foster City, CA, USA) have been relatively well-investigated for the prevention of MTCT. 17 A recent meta-analysis, including five randomised controlled trials (RCT), reported that lamivudine showed a 71% risk reduction compared to the control group. 18 In addition, the latest meta-analysis, including four RCTs, reported similar risk reduction in MTCT (77%) using telbivudine without serious adverse events. 18 Despite of their efficacy, however, there were still concerns of developing resistant mutants in spite of the short therapy duration. 19, 20 Therefore, lamivudine and telbivudine are limited by a low threshold to resistance and multiplying viral quasi-species that might make treatment in future pregnancies difficult. [19] [20] [21] [22] In this regard, majority of worldwide guidelines [23] [24] [25] [26] recommend tenofovir as the preferred choice for MTCT prevention in terms of anti-viral potency, available safety data during pregnancy, and concerns for resistance compared to other anti-viral agents. To date, a small number of case series and relatively well-designed non-randomised controlled trials (NRCT) using tenofovir have been conducted recently. [27] [28] [29] [30] [31] [32] [33] [34] [35] Recently, Pan et al. 36 published the first multicenter RCT with a high quality of evidence. The authors found 75% risk reduction for tenofovir with comparable safety outcomes compared to the control group. 36 However, since there is only one RCT currently available, there are still concerns whether 1 RCT provides sufficient evidence to disregard all the NRCTs. Because well-designed observational studies are not necessarily more biased than RCTs, including observational studies increases the sample size and establishes more solid evidence if the study design is the single reason for the possible discrepancy. 37, 38 Therefore, we conducted a systematic review and meta-analysis of tenofovir for prevention of perinatal HBV transmission to better determine the efficacy and safety of tenofovir.
| MATERIALS AND METHODS
| Search strategy
This meta-analysis was performed according to the PRISMA statement for reporting of systematic reviews and meta-analyses. 39 PubMed, EMBASE, and Cochrane databases were searched for English-language articles published from database inception through August 16, 2016. The detailed search strategy and search terms are available in Table S1 . To supplement electronic searches, the links of every search result and all references in the pertinent articles were reviewed to identify additional literature that was not indexed.
| Eligibility criteria
Two independent investigators (MHH and JHK) identified comparative, peer-reviewed studies of second or third trimester tenofovir administration vs. controls for pregnant patients with chronic HBV infection that included objective evaluations of maternal and/or foetal safety outcomes and non-comparative case series that assessed the MTCT rate and evaluated maternal and foetal safety outcomes.
If multiple publications reported on the same population, the most recent or most comprehensive data were chosen. Only data of conference abstracts were excluded. The detailed trial selection process is summarised in Figure S1 . Any disagreement was resolved by consensus or referral to a third investigator (JEY).
| Data extraction and risk of bias assessment
The same two investigators independently performed data extrac- 
| Outcome measurements
The maternal efficacy outcomes included HBV DNA suppression, ALT normalisation, and HBeAg seroconversion. MTCT rates were defined as HBsAg or HBV DNA positivity of newborns and of infants at 6-12 months of age. 15 Maternal safety outcomes included creatinine kinase (CK) elevation, serum creatinine (Cr) elevation, ALT flare, caesarean section (CS) and post-partum haemorrhage rate.
Foetal safety outcomes included congenital malformation, pre-term birth rate, low birth weight (<2500 g), and foetal death.
| Statistical analysis
The pooled log-transformed odds ratio (OR) and the 95% confidence interval (CI) were provided in a forest plot for dichotomised outcomes. Heterogeneity between studies for each of the outcomes was tested with both the v 2 test and I 2 statistics. 43 A Mantel-Haenszel random-effects meta-analysis was performed in outcomes in consideration of the inter-study heterogeneity. 44 The overall intervention effect achieved statistical significance if the two-sided p-value was <.05. All statistical analyses were performed using the 3 | RESULTS
| Characteristics of the studies
The detailed study selection process is described in Figure S1 . In this study, 10 studies (one RCT, four NRCT, and five case series) with a total of 733 pregnant women were included. Among them, five comparative trials (one RCT, four NRCT) with 599 pregnant women were pooled for analysis. [27] [28] [29] [30] 36 The characteristics of the included comparative trials are summarised in Table 1 . The RCT was a multicentre trial conducted in five geographic regions in China. 36 The four NRCTs were performed in Turkey, Australia, Taiwan, and Canada. [27] [28] [29] [30] In all studies, tenofovir was administered in the second or third trimester to pregnant women who were HBeAg positive and had high maternal HBV DNA (more than 2910 5 IU/mL). Both tenofovir and control group infants received the hepatitis B vaccine with the hepatitis B immunoglobulin (HBIG) at birth. The mean maternal age was 29.7 years. Most of enrolled mother were HBeAg positive (>95%) except for one trial. 30 The risk of bias for the RCT was high attributa-
ble to the open label study design. 36 One of four NRCT was assigned as high level of risk of bias owing to the different inclusion criteria among the groups and insufficient follow-up periods. 30 The detailed risk of bias measurement results are shown in Tables S2 and S3. 3.2 | Maternal efficacy outcomes and MTCT rate
The maternal efficacy outcomes and MTCT rate of the included trials are described in Two studies (1 RCT and 1 NRCT) reported newborn HBsAg seropositivity and HBV-DNA levels within 24 hours after birth. 29, 36 The newborn HBsAg positive rates were 8.0% ( 
P=.0002, I
2 =0%) ( Figure 1D ). None of the studies showed HBV DNA levels of infants within 6-12 months.
| Maternal and foetal safety outcomes
The forest plots of odds ratio (OR) for maternal safety outcomes are shown in Figure 2 . The tenofovir group showed a similar CK eleva- , less than 50 IU/mL for Celen et al. 27 , and less than 1 000 000 IU/mL for Chen et al. 
| Case series analysis
The summary of the case series analyses is displayed in Table 4 . Five case series analyses with a total of 134 pregnant women were included. The administration of tenofovir showed decreased maternal HBV DNA levels from 9.38 log 10 copies/mL to 3.55 log 10 copies/mL. 32, 34, 35 Two cases (2/134 [1.5%]) of MTCT were reported.
The first case had an extremely high serum maternal HBV DNA level (152 000 000 copies/mL) and began tenofovir at gestational week 28. 32 In the other case, the mother was treated with tenofovir for only 17 days due to non-compliance with pre-natal care. 34 Regarding safety, a total of four cases (3.0% [4/134] ) of serious adverse events were described in the case series: one case of hypospadias, 32 one case of post-partum haemorrhage, 33 one case of patent foramen ovale 33 and one case of congenital dislocation of the right knee. 33 However, there were no known foetal deaths after tenofovir treatment. The risk of bias of the case series is shown in Table S4 . level (less than 10 6 copies/mL vs. more than 10 8 copies/mL; <3% vs.
RCT
10%-30%). [10] [11] [12] [13] [14] [15] [16] Therefore, a growing number of reports have been published about the use of antepartum anti-viral therapy to reduce MTCT in this population.
Among the current FDA approved drugs, tenofovir disoproxil fumarate is the only preferred first-line agent for the treatment of chronic HBV infection. 23, 24, 47 The first use of tenofovir to prevent MTCT was reported in 2012. 31 F I G U R E 2 Forest plots of odds ratios for maternal safety outcomes. CI, confidence interval; CK, creatinine kinase; Cr, serum creatinine; ALT, alanine aminotransferase; CS, caesarean section. The size of the squares indicates point estimates and the weight of each study. The horizontal lines show 95% confidence intervals group) with a mean age of 27.7AE3.7 years who were HBeAg positive with high HBV DNA levels (>2910 6 IU/mL) in 6 Turkish hospitals. 27 The reported MTCT rate was 0% (0/21) in infants born to the women who received tenofovir therapy compared with 8% (2/24) in infants born to women in the control group (P=.194). There were no differences between the groups in terms of adverse events in mothers or congenital deformities. Later, Greenup et al., 28 Chen et al., 29 and
Samadi Kochaksaraei et al. 30 reported similar NRCT comparing tenofovir administration in the second or third trimester and control groups for women with HBeAg positivity and high maternal HBV infection. HBsAg positive rate in infants 6-12 months of age at least 1 month after the last vaccination. However, as mentioned at result, this study had significant methodological problems including different inclusion criteria between the tenofovir and control groups and inadequate follow-up periods. Therefore, we analysed the efficacy of tenofovir through NRCTs including and excluding this study 30 and confirmed the benefit of tenofovir for MTCT in both analyses.
The first RCT of tenofovir was published in June 2016, demonstrating that the MTCT rate (defined as HBsAg positivity of infants at 6-12 months of age) of tenofovir was significantly lower than that of the placebo group (intention-to-treat analysis: 18% vs. 5%; P=.007) without identified safety issues (birth defect rate, 2% vs. 1%; P=1.000).
36
Although robust data are available from this study, more evidence is needed to consider tenofovir as the first-line anti-viral therapy to prevent MTCT. However, there is only one previous meta-analysis analysing three NRCT for tenofovir that mainly focused on other anti-viral therapies including lamivudine and telbivudine. 18 To the best of our knowledge, this is the first systematic review and meta-analysis to evaluate the efficacy and safety of tenofovir for reducing the risk of MTCT.
In this meta-analysis, we demonstrated that tenofovir treatment in HBV infected mothers, as compared with controls (immunoprophylaxis only), reduced the MTCT rate by 77%, as indicated by serum HBsAg levels of infants at 6-12 months of age with a low degree of heterogeneity (I 2 =0%). The only identified side effect was maternal CK level elevation in the tenofovir group compared to controls, but the statistical significance was borderline (P=.50). Moreover, there was no identified muscle dysfunction or muscular pain, and most cases of CK elevation were asymptomatic. Other major foetal safety parameters including congenital malformation and foetal death were comparable in this analysis.
Previous meta-analyses have shown the efficacy and safety of other anti-viral agents ( 
, Celen et al. 27 , >59ULN for Chen et al. 29 1 Torticollis and umbilical hernia. Hypospadias.
3
Unilateral deafness. 4 Polydactyly of the left thumb. 5 Chromosomal abnormality.
HYUN ET AL.
| 1501 reduction in MTCT, which is a more cost-effective agent than other agents in China. 18, 50, [52] [53] [54] [55] Despite similar efficiency, tenofovir has a higher resistance barrier with no resistance identified after 6 years follow-up when comparing two agents. 23, 47, 56, 57 Regarding foetal safety, According to the Antiretroviral Pregnancy Registry (APR) for evaluating the effect of anti-viral agents against human immunodeficiency virus (HIV) infection, the prevalence of birth defects in foetus were 2.8% (208/7311) for lamivudine, 0% (0/9) for telbivudine and 2.0% (28/1412) for tenofovir. 58 Even some studies have reported that tenofovir-exposed foetuses showed declined foetal and infantile growth retardation due to bone density and mineral contents changes, 59, 60 the adverse event data according to both the APR and cumulative clinical experience for HIV patients' data demonstrated that tenofovir can be safely used to treat pregnant women. 58, 61 The details of risk summary and clinical consideration which labelled in FDA are summarised in HBsAg positive infants within 6-12 months.
the limited duration of tenofovir treatment (up to 27 weeks from 2nd trimester). In a pivotal study of tenofovir in HBeAg positive patients, the HBV DNA suppression rate (<400 copies/mL) after 48 weeks of tenofovir treatment was 76%. 47 
